A 2-stage, Phase 2a Study to Evaluate the Efficacy, Safety, and Tolerability of OLP-1002 Subcutaneous Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in a Hip and/or Knee Joint
Latest Information Update: 15 May 2024
At a glance
- Drugs OLP 1002 (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors OliPass
Most Recent Events
- 08 May 2024 Status changed from recruiting to completed.
- 13 Nov 2023 Results presented in an OliPass media release.
- 13 Nov 2023 According to an OliPass media release, the interim analysis suggested that the study be properly powered for efficacy if evaluated in 60 to 90 patients. The study was extended to evaluate additional patients. A preliminary in-house statistical analysis is now available for the extension study employing the additional 59 patients.